Oct 2026· Phytotherapy Research· 0 citations· 32 references
Medicine
TL;DR
It is demonstrated that GMN attenuates renal inflammation, suppresses myofibroblast activation and ECM remodeling by concurrently inhibiting NF-κB/NLRP3 inflammasome axis and TGF-β1/Smad pathway.
Abstract
Chronic kidney disease (CKD) is driven by persistent inflammation and progressive fibrosis, leading to irreversible renal damage. Gramine (GMN), an indole alkaloid, has broad pharmacological benefits. However, its therapeutic potential against renal fibrosis remains unexplored. This study investigates the antifibrotic potential of GMN in an experimental model of CKD. Potential therapeutic targets of GMN associated with renal fibrosis were identified through network analysis, and functional enrichment analysis revealed the mechanisms regulated by these targets. In vitro validation was conducted in transforming growth factor-β1 (TGF-β1)-induced normal rat kidney fibroblast (NRK-49F) cells. Fibrosis in the left kidney was induced by ureter obstruction, and mice received GMN orally at doses of 10 and 30 mg/kg. GMN targets 110 genes related to renal fibrosis that regulate profibrotic pathways, including TGF-β1-mediated canonical Smad signaling. GMN effectively attenuated TGF-β1-induced fibroblast-to-myofibroblast transition by inhibiting Smad signaling, resulting in downregulation of collagen I and fibronectin. In vivo, oral administration of GMN ameliorated the histopathological damage induced by UUO and significantly improved renal function. Mechanistically, GMN suppressed NF-κB-mediated priming of the NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome and inhibited IL-1β maturation, thereby mitigating renal inflammation. UUO-induced fibrotic responses, characterized by upregulation of TGF-β1, TGF-β receptor type II, p-Smad2/3, connective tissue growth factor (CTGF), alpha-smooth muscle actin, and extracellular matrix (ECM) components were significantly attenuated by GMN, suggesting its ability to inhibit pathological ECM remodeling. This study demonstrates that GMN attenuates renal inflammation, suppresses myofibroblast activation and ECM remodeling by concurrently inhibiting NF-κB/NLRP3 inflammasome axis and TGF-β1/Smad pathway.
These findings support a model in which tubular DMT1 integrates iron overload, ferroptotic stress, and TGF-β1-Smad signaling during fibrotic progression in CKD, and may offer a tubular-selective therapeutic strategy for CKD.
Ying Pan, Mei-Qi Liu, Jia-Wei Qiu et al.· Antioxidants and Redox Signa...· 0 citations
Renal fibrosis represents the final common pathway in the progression of chronic kidney disease (CKD), characterized by excessive deposition of extracellular matrix (ECM) and progressive disruption of renal architecture. To date, no approved therapy can fully reverse established or advanced fibrosis. This review compre...
Yang-Yang Cai, Qian Wu, Fang Dou et al.· Experimental and molecular p...· 0 citations
HMGN5 is identified as a novel regulator of IFNAR2-related pyroptosis-associated signaling in renal tubular epithelial cells and it is suggested that the HMGN5-IFNAR2 axis represents a pathophysiological pathway of interest in CKD that warrants further investigation.
Xue Rong, Jing Xu, Jie-Nan Zhang et al.· International Journal of Mol...· 0 citations
This study examined the protective effects of Rg5 against renal fibrosis and elucidated its underlying immunomodulatory mechanisms. A mouse model of renal fibrosis was generated through adenine administration, and Rg5 was administered orally to assess its preventative effects. Renal tubular epithelial cells (RTECs, HK-...
Jiang-Tao Zhong, Zi-Yi Xu, Ze-Long Wang et al.· International Immunopharmaco...· 0 citations
Renal fibrosis is a hallmark of chronic kidney disease (CKD), but effective antifibrotic therapies are lacking. Pentraxin 3 (PTX3) is markedly upregulated in CKD patients and in a unilateral ureteral obstruction (UUO) model, correlating with renal injury, extracellular matrix accumulation, partial epithelial-mesenchyma...
In a unilateral ureteral obstruction-induced CKD mouse model, QCT treatment attenuated tubular injury, improved renal function, and reduced fibrosis markers such as fibronectin, Col1a1, and α-SMA.